<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tinidazole: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tinidazole: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tinidazole: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10205" href="/d/html/10205.html" rel="external">see "Tinidazole: Drug information"</a> and <a class="drug drug_patient" data-topicid="11539" href="/d/html/11539.html" rel="external">see "Tinidazole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708927"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Carcinogenic:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Limit use to approved indications only. Avoid chronic use.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1039011"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Amebicide</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Antiprotozoal, Nitroimidazole</span></li></ul></div>
<div class="block dop drugH1Div" id="F228042"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1e466b6-4a5a-4b2f-af12-54997f207d89">Amebiasis, intestinal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amebiasis, intestinal:</b> Children &gt;3 years and Adolescents: Oral: 50 mg/kg/dose once daily for 3 days; maximum daily dose: 2,000 mg/<b>day</b>; for patients with severe and extraintestinal disease, administer for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8610ddeb-9e9f-4059-8beb-59ccfba98e2c">Amebiasis, liver abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amebiasis, liver abscess:</b> Children &gt;3 years and Adolescents: Oral: 50 mg/kg/day for 3 to 5 days; maximum daily dose: 2,000 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f74ecf56-4df6-48d7-b60e-9165458d8fec">Bacterial vaginosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial vaginosis:</b> Adolescents: Oral: 2,000 mg once daily for 2 days <b>or</b> 1,000 mg once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa429f9a-ea7a-4d90-8746-55a38cb83631">
<i>Blastocystis hominis</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Blastocystis hominis</i> infection:</b> Limited data available: Children ≥3 years and Adolescents: Oral: 50 mg/kg as a single dose; maximum dose: 2,000 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a7088e0-7d0f-47f9-85ee-4c73938d530d">Giardiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giardiasis:</b> Children &gt;3 years and Adolescents: Oral: 50 mg/kg as a single dose; maximum dose: 2,000 mg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82d25e57-655b-43b7-909f-b9220bfdb9a2">
<i>Helicobacter pylori</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori</i> infection:</b> Limited data available: Children &gt;3 years and Adolescents: Oral: 20 mg/kg/day in 1 to 2 divided doses for 5 to 7 days in combination with other agents; some studies have used a longer duration of 2 to 6 weeks; maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16285942','lexi-content-ref-9651466','lexi-content-ref-11129216','lexi-content-ref-1446854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16285942','lexi-content-ref-9651466','lexi-content-ref-11129216','lexi-content-ref-1446854'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e3b92da-fcc4-4d5d-89cd-a6cbd0a5ada5">Trichomoniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trichomoniasis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>)<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary therapy</i>: Adolescents: Oral: 2,000 mg as a single dose; sexual partners should be treated concomitantly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Persistent, recurrent, after metronidazole treatment failure:</i> Adolescents: Oral: 2,000 mg once daily for 7 days. <b>Note:</b> Ensure reinfection has not occurred prior to initiation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3fd26f11-1af1-4e70-b617-c8cbe0250c68">Urethritis, nongonococcal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urethritis, nongonococcal (recurrent or persistent urethritis in males who have sex with females and who live in regions where <i>T. vaginalis</i> is prevalent): </b>Adolescents: Oral: 2,000 mg as a single dose. <b>Note:</b> Compliance with initial regimen and lack of reexposure to an untreated sex partner should be excluded prior to use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192762"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children &gt;3 years and Adolescents: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Approximately 43% removed during a 6-hour session; an additional dose equal to <sup>1</sup>/<sub>2</sub> the usual dose should be administered at the end of hemodialysis if tinidazole is administered prior to hemodialysis on dialysis days</p></div>
<div class="block dohp drugH1Div" id="F51192763"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block doa drugH1Div" id="F228033"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10205" href="/d/html/10205.html" rel="external">see "Tinidazole: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1e466b6-4a5a-4b2f-af12-54997f207d89">Amebiasis, intestinal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amebiasis, intestinal:</b>
<b>Oral:</b> 2 g once daily for 3 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8610ddeb-9e9f-4059-8beb-59ccfba98e2c">Amebiasis, liver abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amebiasis, liver abscess:</b>
<b>Oral:</b> 2 g once daily for 3 to 5 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f74ecf56-4df6-48d7-b60e-9165458d8fec">Bacterial vaginosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial vaginosis (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment is generally not warranted for patients who are asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 g once daily for 5 days <b>or</b> 2 g once daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-17666604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-17666604'])">Ref</a></span>); some experts prefer 1 g once daily for 5 days due to improved efficacy and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17666604','lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17666604','lexi-content-ref-Sobel.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">For multiple disease recurrences, 500 mg twice daily for 7 days in combination with or prior to a multiweek course of boric acid, followed by suppressive topical therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-19704395','lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-19704395','lexi-content-ref-Sobel.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a7088e0-7d0f-47f9-85ee-4c73938d530d">Giardiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giardiasis:</b>
<b>Oral:</b> 2 g as a single dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori</i></b>
<b> eradication (off-label use): Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">American College of Gastroenterology guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17608775','lexi-content-ref-28071659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17608775','lexi-content-ref-28071659'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Concomitant regimen: </i>500 mg twice daily in combination with clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, and a standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Sequential regimen</i>: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, tinidazole 500 mg twice daily, and a standard-dose proton pump inhibitor daily for 5 to 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hybrid regimen</i>: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, tinidazole 500 mg twice daily, and a standard-dose proton pump inhibitor twice daily for 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e3b92da-fcc4-4d5d-89cd-a6cbd0a5ada5">Trichomoniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trichomoniasis (index case and sex partner):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial treatment (alternative agent): <b>Oral:</b> 2 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>) or 500 mg twice daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34370424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34370424'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Refractory infection (off label):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients with suspected reinfection because of re-exposure to an untreated partner may receive a regimen used for initial treatment. For others, clinicians may request a kit from the CDC to perform drug-resistant testing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Females without re</i>
<i>-exposure:</i>
<b>Oral:</b> 2 g once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Females with infection refractory to multiple prior regimens:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Combination therapy with oral and intravaginal tinidazole:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 2 g once daily in combination with intravaginal tinidazole for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Intravaginal:</b> 500 mg twice daily in combination with oral tinidazole for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-11565074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-11565074'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Combination therapy with oral tinidazole and intravaginal paromomycin or boric acid: <b>Oral:</b> 1 g 3 times daily for 14 days in combination with intravaginal paromomycin for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-30106840','lexi-content-ref-26267873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-30106840','lexi-content-ref-26267873'])">Ref</a></span>) or intravaginal boric acid for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575848'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991973"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: An additional dose equal to ½ the usual dose, should be administered at the end of hemodialysis if tinidazole is administered prior to hemodialysis on a dialysis day.</p></div>
<div class="block doha drugH1Div" id="F50989269"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.</p></div>
<div class="block adr drugH1Div" id="F227996"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in pediatric patients and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (≤2%), anorexia (2% to 3%), constipation (≤1%), decreased appetite (&gt;2%), dyspepsia (≤2%), epigastric discomfort (≤2%), flatulence (&gt;2%), nausea (3% to 5%), vomiting (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (&gt;2%), pelvic pain (&gt;2%), urinary tract infection (&gt;2%), urine abnormality (&gt;2%), vulvovaginal candidiasis (5%), vulvovaginal disease (discomfort or odor) (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Bitter taste (≤6%), dizziness (≤1%), fatigue (≤2%), headache (≤1%), malaise (≤2%), metallic taste (≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (&gt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hairy tongue</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Coma, confusion, depression</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, pharyngitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, oral candidiasis, salivation, stomatitis, tongue discoloration, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dark urine, vaginal discharge</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (overgrowth)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, burning sensation, drowsiness, insomnia, peripheral neuropathy (transient; includes numbness and paresthesia), seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including acute or severe hypersensitivity reaction)</p></div>
<div class="block coi drugH1Div" id="F228011"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tinidazole, nitroimidazole derivatives, or any component of the formulation; Cockayne syndrome.</p></div>
<div class="block war drugH1Div" id="F227994"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinogenic: <b>[US Boxed Warning]: Carcinogenicity has been observed with another nitroimidazole derivative (metronidazole) in animal studies;</b>
<b>use should be reserved for approved indications only. Avoid chronic use.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Seizures and peripheral neuropathy (eg, extremity numbness and paresthesia) have been reported with tinidazole and other nitroimidazole derivatives; discontinue treatment if abnormal neurologic signs or symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD), pseudomembranous colitis, and/or vaginal candidiasis. CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: Use with caution in patients with current or a history of blood dyscrasias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p></div>
<div class="block foc drugH1Div" id="F228005"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F227992"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422283"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tinidazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $5.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $10.15 - $12.69</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block exp drugH1Div" id="F228009"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>67 mg/mL oral suspension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 67 mg/mL suspension may be made with tablets and cherry syrup. Crush four 500 mg tablets in a mortar and reduce to a fine powder. Add 10 mL cherry syrup and mix until smooth; transfer to a graduated bottle. Rinse mortar with cherry syrup several times to transfer any remaining drug into the bottle, and add additional cherry syrup to the bottle to a final volume of 30 mL. Label "shake well". Stable for 7 days at room temperature.</p>
<div class="reference">Tindamax (tinidazole) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; June 2019.</div>
</div>
<div class="block admp drugH1Div" id="F52613932"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:  Administer with food to minimize gastrointestinal adverse effects. </p></div>
<div class="block adm drugH1Div" id="F228007"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravaginal (off-label route):</b> Administer tablet intravaginally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11565074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11565074'])">Ref</a></span>). Do not use tampons, douches, spermicides, or other vaginal products or have vaginal intercourse during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F228023"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53569144"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of giardiasis caused by <i>Giardia duodenalis</i> (<i>Giardia lamblia</i>) (FDA approved in ages &gt;3 years and adults); treatment of intestinal amebiasis and amebic liver abscess caused by <i>Entamoeba histolytica</i> (FDA approved in ages &gt;3 years and adults); treatment of trichomoniasis caused by <i>Trichomonas vaginalis</i> (FDA approved in adults); treatment of bacterial vaginosis (FDA approved in nonpregnant adult females).</p></div>
<div class="block cyt drugH1Div" id="F228043"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F227999"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Tinidazole may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: Tinidazole may enhance the adverse/toxic effect of Disulfiram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F228024"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Peak antibiotic serum concentration lowered and delayed, but total drug absorbed not affected. Management: Administer with food.</p></div>
<div class="block dic drugH1Div" id="F228015"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">The manufacturer recommends that ethanol be avoided during treatment and for 3 days after therapy is complete.</p></div>
<div class="block pri drugH1Div" id="F228013"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tinidazole crosses the human placenta and enters the fetal circulation (Karhunen 1984).</p>
<p style="text-indent:0em;margin-top:2em;">Bacterial vaginosis and trichomoniasis are associated with adverse pregnancy outcomes and treatment during pregnancy is recommended. However, due to adverse events observed in animal reproduction studies and limited human data, use of agents other than tinidazole in pregnant patients is preferred (CDC [Workowski 2021]).</p></div>
<div class="block pha drugH1Div" id="F227993"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">After diffusing into the organism, it is proposed that tinidazole causes cytotoxicity by damaging DNA and preventing further DNA synthesis.</p></div>
<div class="block phk drugH1Div" id="F228010"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and complete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~50 L; distributes to most body tissues and fluids; crosses the blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 12%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 (primarily); undergoes oxidation, hydroxylation and conjugation; forms a metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 13.2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1.6 hours (fasting, delayed ~2 hours when given with food)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~20% to 25%); feces (~12%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F228016"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tiniba | Trichogin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Gynormal | Ladylen duo</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Simplotan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Protogyn | Tinizol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Datizole | Fasigyne</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tinidazol | Trichosept</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amplium | Facyl-500 | Fasigyn | Ginosutin | Pletil | Tinidazol | Tinoral | Trinizol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Amtiba | Tinidazole tm</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Fasigyn forte | Silesin | Tinidazol | Triconidazol | Troxxil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jin he | Kai fu xin | Le jing | Lizhu kuaifujing | Sen di | Tai fu ding</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Amebend | Amebiacyt | Amebion | Amein | Amibiol | Antameb | Biodazol | Bionidazol | Drameba | Entamoxol | Fasigyn | Finameb | Flenidazol | Indazol | Maxipar | Membitrol | Membritol | Rezol | Tidazyn | Tinamid | Tindazeb | Tinidal | Tinidameb | Tinidazol | Tinidazol MK | Triamil | Tricoameb | Tromidal | Tromizer | Zoltifar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Simplotan | Sorquetan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ametricid | Estovyn T | Fasigyn | Proquis | Tinidafran | Tinidameb | Tinidazol | Tinidral | Tinigrun | Tinox | Tizol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fasdal | Fasigyn | Sip | Tenibex | Tinidameb | Tinidan | Tinidazol | Tinidazol la sante | Tinidazol MK | Tinigen | Tinigrun | Troxxil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tiniba | Tinidazol | Tricanix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Protozole</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tricolam</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Amtiba | Astiba | Tiniba | Tinirem</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tinigyn | Tricanix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fasigyne</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Flatin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Protocide</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Altizole | Baltin | Costini | Cozit | Enidazol | Fasigyn | Fasigyn ds | Protobid | Tina | Tinalar | Tinamide | Tini | Tiniba | Tinidafyl | Tinifas | Tinitag | Tinivista | Tinvista | Tiz | Tizole | Todaz | Tridazole | Wondazole</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fasigin | Trimonase</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Protogyn | Sporinex | Tinazol | Tinogyn</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Haisigyn</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Amtiba | Fasigyn | Gratin | Quadran | Tidaz | Tidazol | Tinagyn | Tinda | Tindaz | Tini | Tinibulk | Tinicure | Tinidamed | Tinifil | Tinifred | Tinika | Tinimed | Tinisky | Tinizol | Tinycos | Tizole | Tricogyn | Tynazole | Tzex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Austin tinidazole | Dismel | Fasigyn | Fasozil | Korus tinidazole | Modazole | Pasozil | Tinasol | Tindazole | Tinedarin | Tinidazin | Tinidazol | Tinidazole namyang | Tinozol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Protogyn</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tiniba | Tinidazol | Trichosept</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tiniba | Tinidazol | Tinidazole Polpharma | Trichosept</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Fasigyne | Trichogin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amebysol | Ametricid | Estovyn T | Fasigyn | Induken | Lumenta | Tinidazol | Tinidex | Trinigyn | Triseptil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Camitol | Fasigyn | Sporinex | Tinirem</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Tinimark | Tinizol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Fasigyne</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dyzole</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tinidal | Tinidazol | Tinidazol genfar | Triconidazol | Troxxil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Prevent | Tindamax | Tinida | Trichogin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fasigin | Simplotan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tindamax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tinidazol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Gingitex | Tinidazol genfar | Tinidazol quimfa | Tricor | Troxxil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Protogyn</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tiniba | Tinidazol | Tinidazol-akri | Tinisan | Vero tinidazol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Protogyn</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tinedarin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Asiazole-tn | Fasigyn | Funida | Gynogena | Hugyn | Idazole | Leuco | Pagin | Phardazole | Sporinex | T.m.dazole | Tinazole | Tini | Tivagil | Tonid | Tricban | Tricban foil | Trichonas | Tricogyn | Tricogyn-500 | Tricomed | Tricozone | Trigyn</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fasigyne</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Asgin | Cancidin | Enagyn | Fanda | Fasigyn | Fudagyn | Su fu dou | Tibican | Tibidin | Tidazol | Tinizin | Tinizol | Tinizole | Tricanix | Trichogin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Tiniba | Tinidazol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Astiba | Tidazol | Tin tin | Tinazol | Tini | Tiniba</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Tricur</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn | Pangamil | Tinidazol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fasigyn</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Amtiba | Fasigyn | Tiniba | Tinifil | Tinizol | Tizole</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825. doi: 10.1111/j.1572-0241.2007.01393.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4039599">
<a name="4039599"></a>Evaldson GR, Lindgren S, Nord CE, Rane AT. Tinidazole milk excretion and pharmacokinetics in lactating women. <i>Br J Clin Pharmacol</i>. 1985;19(4):503-507. doi: 10.1111/j.1365-2125.1985.tb02676.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/4039599/pubmed" id="4039599" target="_blank">4039599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16285942">
<a name="16285942"></a>Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-day sequential treatment for <i>Helicobacter pylori</i> eradication in children: a randomized trial. <i>Gastroenterology</i>. 2005;129:1414-1419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/16285942/pubmed" id="16285942" target="_blank">16285942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30106840">
<a name="30106840"></a>Henien M, Nyirjesy P, Smith K. Metronidazole-resistant trichomoniasis: beneficial pharmacodynamic relationship with high-dose oral tinidazole and vaginal paromomycin combination therapy. <i>Sex Transm Dis</i>. 2019;46(1):e1-e2. doi:10.1097/OLQ.0000000000000903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/30106840/pubmed" id="30106840" target="_blank">30106840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6487467">
<a name="6487467"></a>Karhunen M. Placental transfer of metronidazole and tinidazole in early human pregnancy after a single infusion. <i>Br J Clin Pharmacol.</i> 1984;18(2):254-257. doi: 10.1111/j.1365-2125.1984.tb02465.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/6487467/pubmed" id="6487467" target="_blank">6487467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26267873">
<a name="26267873"></a>Keating MA, Nyirjesy P. Trichomonas vaginalis infection in a tertiary care vaginitis center. <i>Sex Transm Dis</i>. 2015;42(9):482-485. doi:10.1097/OLQ.0000000000000334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/26267873/pubmed" id="26267873" target="_blank">26267873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10384859">
<a name="10384859"></a>Lamp KC, Freeman CD, Klutman NE, “Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials,” <i>Clin Pharmacokinet</i>, 1999, 36(5):353-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/10384859/pubmed" id="10384859" target="_blank">10384859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12920490">
<a name="12920490"></a>Li XQ, Bjorkman A, Andersson TB, et al. Identification of Human Cytochrome P(450)s that Metabolise Anti-Parasitic Drugs and Predictions of <i>in vivo</i> Drug Hepatic Clearance from <i>in vitro</i> Data. <i>Eur J Clin Pharmacol.</i> 2003;59(5-6):429-442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/12920490/pubmed" id="12920490" target="_blank">12920490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17666604">
<a name="17666604"></a>Livengood CH 3rd, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. <i>Obstet Gynecol</i>. 2007;110(2, pt 1):302-309. doi:10.1097/01.AOG.0000275282.60506.3d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/17666604/pubmed" id="17666604" target="_blank">17666604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6356785">
<a name="6356785"></a>Männistö PT, Karhunen M, Koskela O, Suikkari AM, Mattila J, Haataja H. Concentrations of tinidazole in breast milk. <i>Acta Pharmacol Toxicol (Copenh).</i> 1983;53(3):254-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/6356785/pubmed" id="6356785" target="_blank">6356785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9651466">
<a name="9651466"></a>Moshkowitz M, Reif S, Brill S, Ringel Y, Arber N, Halpern Z, Bujanover Y. One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for <i>Helicobacter pylori</i> infection in children and adolescents. <i>Pediatrics</i>. 1998;102(1):e14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/9651466/pubmed" id="9651466" target="_blank">9651466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11129216">
<a name="11129216"></a>Nijevitch AA, Farztdinov KM, Sataev VU, et al. <i>Helicobacter pylori infection</i> in childhood: results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole. <i>Journal of Gastroenterology and Hepatology</i>. 2000;15:1243-1250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/11129216/pubmed" id="11129216" target="_blank">11129216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1446854">
<a name="1446854"></a>Odera G, Vaira D, Ainley C, et al. Eighteen month follow up of <i>Helicobacter pylori</i> positive children treated with amoxicillin and tinidazole. <i>Gut</i>. 1992;33:1328-1330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/1446854/pubmed" id="1446854" target="_blank">1446854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19704395">
<a name="19704395"></a>Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. <i>Sex Transm Dis</i>. 2009;36(11):732-734. doi:10.1097/OLQ.0b013e3181b08456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/19704395/pubmed" id="19704395" target="_blank">19704395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575848">
<a name="30575848"></a>Salas A, Hamill MM, Tuddenham S. Nitroimidazole resistance in trichomonas vaginalis infection: a teachable moment.<i> JAMA Intern Med</i>. 2019;179(2):247-248. doi:10.1001/jamainternmed.2018.7241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/30575848/pubmed" id="30575848" target="_blank">30575848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sobel.1">
<a name="Sobel.1"></a>Sobel JD. Bacterial vaginosis: Initial treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11565074">
<a name="11565074"></a>Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis.<i> Clin Infect Dis</i>. 2001;33(8):1341-1346. doi:10.1086/323034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/11565074/pubmed" id="11565074" target="_blank">11565074</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tindamax (tinidazole) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7118775">
<a name="7118775"></a>Wood BA, Faulkner JK, Monro AM. The pharmacokinetics, metabolism and tissue distribution of tinidazole. <i>J Antimicrob Chemother</i>. 1982;10(suppl A):43-57. doi:10.1093/jac/10.suppl_a.43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/7118775/pubmed" id="7118775" target="_blank">7118775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA; Centers for Disease Control and Prevention (CDC). Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep. </i>2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexuallytransmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34370424">
<a name="34370424"></a>World Health Organization (WHO). Guidelines for the management of symptomatic sexually transmitted infections. Geneva: World Health Organization; 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tinidazole-pediatric-drug-information/abstract-text/34370424/pubmed" id="34370424" target="_blank">34370424</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 95047 Version 135.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
